文献速递糖尿病

可溶性尿激酶纤溶酶原激活物受体预测1型糖尿病心血管事件、肾功能下降与死亡

Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
PubMed 文献 · Diabetes Care · 2019-03-18

该前瞻性研究纳入667例不同白蛋白尿程度的1型糖尿病患者,随访5.2至6.2年,发现suPAR每翻倍与心血管事件、eGFR下降≥30%及死亡独立相关,并可显著改善这些终点的判别能力。

要点

  • suPAR每翻倍独立预测1型糖尿病心血管事件(HR 3.13)和死亡(HR 4.13)。
  • suPAR每翻倍独立预测eGFR下降≥30%(HR 2.93),但对白蛋白尿进展和ESRD无显著预测。
  • suPAR可显著改善心血管事件、eGFR下降和死亡的判别能力(rIDI显著)。

核心结论

  • 在1型糖尿病伴不同白蛋白尿程度的患者中,较高的suPAR水平是心血管事件、eGFR下降≥30%和死亡的显著独立危险因素,并显著改善这些终点的判别能力。

研究设计与样本

  • 前瞻性研究纳入667例不同白蛋白尿程度的1型糖尿病患者,随访5.2至6.2年,结果按已知危险因素校正,风险比以suPAR每翻倍表示并计算rIDI。

主要发现

  • suPAR中位数(四分位距)为3.4 ng/mL(2.7-4.5),所有参与者均可定量。
  • 心血管事件(n=94)校正HR 3.13(95%CI 1.96-5.45,P<0.001),rIDI 22.6%(P<0.001)。
  • eGFR下降≥30%(n=93)校正HR 2.93(95%CI 1.68-5.11,P<0.001),rIDI 14.4%(P<0.001)。
  • 死亡(n=58)校正HR 4.13(95%CI 1.96-8.69,P<0.001),rIDI 23.9%(P<0.001)。
  • 白蛋白尿进展(n=36)校正HR 1.27(95%CI 0.51-3.19,P=0.61);ESRD(n=23)校正HR 2.82(95%CI 0.73-11.9,P=0.13)。

临床怎么用

  • 在1型糖尿病管理中,可考虑检测suPAR以辅助识别心血管事件、肾功能下降和死亡高风险患者。

局限性

  • 研究未报告suPAR检测方法、模型校准度及外部验证结果,推广性需进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR's predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: We included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated. RESULTS: Quantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96-5.45, P < 0.001), 1.27 (0.51-3.19, P = 0.61), 2.93 (1.68-5.11, P < 0.001), 2.82 (0.73-11.9, P = 0.13), and 4.13 (1.96-8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001). CONCLUSIONS: In patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Rotbain Curovic V, Theilade S, Winther SA, et al. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. Diabetes Care. 2019. PMID: 30885954. doi:10.2337/dc18-1427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。